These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21695643)

  • 1. Phosphodiesterase inhibition in heart failure.
    Movsesian MA; Kukreja RC
    Handb Exp Pharmacol; 2011; (204):237-49. PubMed ID: 21695643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibition in heart failure.
    Movsesian M; Stehlik J; Vandeput F; Bristow MR
    Heart Fail Rev; 2009 Dec; 14(4):255-63. PubMed ID: 19096931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
    Stehlik J; Movsesian MA
    Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium.
    Vandeput F; Krall J; Ockaili R; Salloum FN; Florio V; Corbin JD; Francis SH; Kukreja RC; Movsesian MA
    J Pharmacol Exp Ther; 2009 Sep; 330(3):884-91. PubMed ID: 19546307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 5 inhibitors: are they cardioprotective?
    Reffelmann T; Kloner RA
    Cardiovasc Res; 2009 Jul; 83(2):204-12. PubMed ID: 19474180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition.
    Qvigstad E; Moltzau LR; Aronsen JM; Nguyen CH; Hougen K; Sjaastad I; Levy FO; Skomedal T; Osnes JB
    Cardiovasc Res; 2010 Mar; 85(4):763-72. PubMed ID: 19900965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.
    Kim GE; Kass DA
    Handb Exp Pharmacol; 2017; 243():249-269. PubMed ID: 27787716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application].
    Guazzi M; Vicenzi M; Samaja M
    G Ital Cardiol (Rome); 2009; 10(11-12):725-37. PubMed ID: 20101899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
    Van Tassell BW; Radwanski P; Movsesian M; Munger MA
    Pharmacotherapy; 2008 Dec; 28(12):1523-30. PubMed ID: 19025433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
    Whalin ME; Scammell JG; Strada SJ; Thompson WJ
    Mol Pharmacol; 1991 Jun; 39(6):711-7. PubMed ID: 1646946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure.
    Morgan JP; Erny RE; Allen PD; Grossman W; Gwathmey JK
    Circulation; 1990 Feb; 81(2 Suppl):III21-32. PubMed ID: 2153479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives].
    Bedioune I; Bobin P; Karam S; Lindner M; Mika D; Lechêne P; Leroy J; Fischmeister R; Vandecasteele G
    Biol Aujourdhui; 2016; 210(3):127-138. PubMed ID: 27813474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
    Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
    Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to targeting PDE3 in cardiovascular disease.
    Movsesian M
    Pharmacol Ther; 2016 Jul; 163():74-81. PubMed ID: 27108947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.